Focus on Axial LengthPhase 2NCT07456488
The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group
A Phase 2 study testing Atropine 0.01% eye drops in people with Focus on Axial Length, run by Liaquat National Hospital & Medical College at 1 site in Pakistan.
Trial summary
In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction Read more about this study
- Who is it for?
- Ages 4 to 16 years
- Conditions the study is for
- Focus on Axial Length
- What is being tested?
- Atropine 0.01% eye drops
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 13 Jul 2025to 30 Apr 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged 4-16 years
- Both genders
- Myopia of baseline SER of -1.00D or more
- Astigmatism less than or equal to -2.50D
- No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)
- No history of other vision-threatening ocular diseases or previous intraocular surgery.
- No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression.
Who cannot join
- Astigmatism ≥ 2.5 D
- Anisometropia>1 D
- Best corrected visual acuity < 0.5 (6/12)
- Prior intraocular surgery
- Allergy to atropine eye drops
- Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
- History of cardiac or significant respiratory diseases
- Lack of consent for participating in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
LiaquatNHMC
Karachi, Sindh
Hina Nadeem, 03252120568, hinanadeem1508@gmail.com
About this study
In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction
- Conditions
- Focus on Axial Length
- Being tested
- Atropine 0.01% eye drops
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atropine 0.01% eye dropsDrug
Eye drops atropine 0.01% given once nightly to group A for 6 months
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | Atropine 0.01% eye drops Receives: Drug: Atropine 0.01% eye drops |
| Group B | No intervention | No eye drops |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in axial length in mm
Axial length is measured at the time of recruiting the participants and after the end of study
Measured: 6 months
Change in refraction in Diopters
Refraction is measured at the start of study then after 6 months of study
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start13 Jul 2025
- Primary completion17 Apr 2026 (estimated)
- Study completion30 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Focus on Axial LengthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Liaquat National Hospital & Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hina Nadeem, Liaquat National Hospital & Medical College
- Investigators
- Hina Nadeem, MBBS, Principal investigator, LNHMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07456488
- Sponsor's protocol ID
- LiaquatNHMC atropine
- Status last verified
- Mar 2026
- First submitted
- 26 Feb 2026
- Last updated
- 6 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group
- ClinicalTrials.gov ID
- NCT07456488
- Acronym / sponsor ID
- LiaquatNHMC atropine
- Conditions
- Focus on Axial Length
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Liaquat National Hospital & Medical CollegeUniversity, hospital or other
- Study start
- 13 Jul 2025 (actual)
- Primary completion
- 17 Apr 2026 (estimated)
- Study completion
- 30 Apr 2026 (estimated)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Drug: Atropine 0.01% eye dropsAtropine 0.01% eye drops |
| Group B | No intervention | –No eye drops |
Who may qualify
- Ages
- 4 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- Children aged 4-16 years
- Both genders
- Myopia of baseline SER of -1.00D or more
- Astigmatism less than or equal to -2.50D
- No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)
Key exclusion criteria (8 listed)
- Astigmatism ≥ 2.5 D
- Anisometropia>1 D
- Best corrected visual acuity < 0.5 (6/12)
- Prior intraocular surgery
- Allergy to atropine eye drops
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atropine 0.01% eye dropsEye drops atropine 0.01% given once nightly to group A for 6 months | Drug | Group A |
Primary outcome
Change in axial length in mm
Time frame: 6 months
Axial length is measured at the time of recruiting the participants and after the end of study
Change in refraction in Diopters
Time frame: 6 months
Refraction is measured at the start of study then after 6 months of study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hina Nadeem, MBBS principal investigator
LNHMC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Atropine 0.01% eye drops in people with Focus on Axial Length, run by Liaquat National Hospital & Medical College at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hina Nadeem, MBBS (03252120568, hinanadeem1508@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in axial length in mm (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2026.